PharmaCyte Biotech Inc (PMCB): Threshold Pharmaceuticals (NASDAQ

Next 10 Prev Next

Send PM Follow Ignore

Followers	369
Posts	24394
Boards Moderated	1
Alias Born	07/11/2011

Cool_Trades

Re: DITRstocks post# 7678

Thursday, 05/02/2013 8:34:33 AM

Thursday, May 02, 2013 8:34:33 AM

Threshold Pharmaceuticals (NASDAQ – THLD) has a targeted prodrug therapy solution used in conjunction with Gemzar® to determine OS and other endpoints in a segment of pancreatic cancer patients. The therapy is currently in Phase 2 clinical trials and investors are awaiting top-line results. We should note that THLD also has a drug in Phase 3 clinicals and has partnered with a major firm for development and licensing which could lead to over $550 in future payments.

$NVLX

GOLD MEDAL PENNY STOCKS

Click HERE for my disclaimer

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent PMCB News

Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent PMCB News

More PMCB News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent PMCB News

Go Ad-Free